Veil-Based Collector Device Enabling Self-Collected Cervicovaginal Sampling for Site-of-Care Primary HPV-Based Cervical Cancer and Sexually Transmitted Infections Screening: A Pilot Feasibility Study in Romania
Ciuhodaru et al.
The finding, in our words
A Romanian pilot of 960 women demonstrated that self-collected cervicovaginal samples using a veil device yielded valid HPV results in 97.7% and STI results in 97.4% of cases, with ambient temperature stability removing cold-chain logistics. This validates the device as a feasible, scalable tool for decentralized cervical cancer and sexually transmitted infection screening programmes.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
For decentralised testing, a study found dry vaginal self-samples using Copan FLOQSwabs stored up to two weeks at room temperature maintain DNA quality. However, first-void urine collected with the Colli-Pee device may be less sensitive for HPV detection, showing lower positivity and higher cycle threshold values, median Ct 30 versus 27 for other samples.
Chu et al., BJOG : an international journal of obstetrics and gynaecology · source ↗
This study found that self-collected vaginal dry swabs provided noninferior sensitivity for detecting high-grade cervical lesions compared to practitioner-collected samples, although specificity was lower.
Hawkes et al., The Journal of molecular diagnostics : JMD (paywalled) · source ↗
The Phase HPV Urine Test detected 14 high-risk HPV types from first-void urine samples, showing 93 per cent concordance with the Roche cobas 4800 reference assay after sequencing adjudication. The test demonstrated high precision, a low limit of detection, and ten-day stability at ambient temperature, supporting non-invasive, self-collected screening to improve access and participation.
Manjeshwar et al., Journal of clinical microbiology · source ↗
Urine microsampling for HPV DNA shows high correlation with cervical infections and enables home self-collection, which simplifies follow-up in vaccine efficacy trials. Establishing standardised sampling guidelines could overcome current variability and support decentralised, patient-centric monitoring of viral endpoints.
Vorsters et al., Human vaccines & immunotherapeutics · source ↗
This meta-analysis found that HPV testing using self-collected vaginal and urine samples showed sensitivities of 88.6% and 81% for detecting cervical precancer. Using a standardised device for first-void urine increased sensitivity to 86.6%, supporting decentralised patient-centric screening, though data on specificity and specific commercial devices were not consistently reported.
Hsiao et al., The journal of obstetrics and gynaecology research (paywalled) · source ↗